Related Experiment Video
Updated: Jun 25, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension
Michele M Castro1, Elen Rizzi, Gerson J Rodrigues
1Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of São Paulo, Ribeirao Preto, SP, Brazil.
Abstract:
Mounting evidence indicates that structural and functional vascular changes associated with two-kidney, one-clip (2K-1C) hypertension result, at least in part, from altered activity of matrix metalloproteinases (MMPs). Because MMPs are upregulated by increased formation of reactive oxygen species (ROS), we hypothesized that antioxidant approaches could attenuate the increases in MMP-2 expression/activity and the vascular dysfunction and remodeling associated with 2K-1C hypertension. Sham-operated or 2K-1C hypertensive rats were treated with tempol 18 mg/kg/day or apocyanin 25 mg/kg/day (or vehicle). Systolic blood pressure was monitored weekly. After 8 weeks of treatment, aortic rings were isolated to assess endothelium-dependent and -independent relaxation. Quantitative morphometry of structural changes in the aortic wall was studied in hematoxylin/eosin sections. Aortic and systemic ROS levels were measured using dihydroethidine and thiobarbituric acid-reactive substances, respectively. Aortic MMP-2 levels and activity were determined by gelatin and in situ zymography, fluorimetry, and immunohistochemistry. Tempol and apocyanin attenuated 2K-1C hypertension (181+/-20.8 and 192+/-17.6 mm Hg, respectively, versus 213+/-18 mm Hg in hypertensive controls; both p<0.05) and prevented the reduction in endothelium-dependent vasorelaxation found in 2K-1C rats. Tempol, but not apocyanin (p>0.05), prevented the vascular remodeling found in 2K-1C rats (all p<0.01). Tempol was more effective than apocyanin in attenuating hypertension-induced increases in oxidative stress (both p<0.05), MMP-2 levels, and MMP-2 activity in hypertensive rats (all p<0.05). Our results suggest that antioxidant approaches decrease MMP-2 upregulation and attenuate the vascular dysfunction and remodeling during 2K-1C hypertension.
Insights
Antioxidants like tempol and apocyanin can reduce blood pressure and improve vascular function in hypertensive rats. Tempol was more effective in preventing vascular remodeling and reducing oxidative stress and MMP-2 activity.
Area of Science:
- Cardiovascular Research
- Hypertension Studies
- Oxidative Stress Research
Background:
- Two-kidney, one-clip (2K-1C) hypertension involves vascular changes linked to matrix metalloproteinases (MMPs).
- Increased reactive oxygen species (ROS) formation upregulates MMPs, suggesting a role for antioxidants in managing hypertension-related vascular issues.
Purpose of the Study:
- To investigate if antioxidant treatments (tempol, apocyanin) can reduce MMP-2 expression/activity.
- To determine if these antioxidants can prevent vascular dysfunction and remodeling in 2K-1C hypertensive rats.
Main Methods:
- Administered tempol or apocyanin to 2K-1C hypertensive rats for 8 weeks.
- Assessed blood pressure, vasorelaxation, vascular remodeling, ROS levels, and MMP-2 expression/activity.
Main Results:
- Both tempol and apocyanin attenuated 2K-1C hypertension and improved endothelium-dependent vasorelaxation.
- Tempol, more effectively than apocyanin, prevented vascular remodeling, reduced oxidative stress, and decreased MMP-2 levels and activity.
Conclusions:
- Antioxidant strategies can decrease MMP-2 upregulation in hypertension.
- These approaches hold potential for attenuating vascular dysfunction and remodeling associated with 2K-1C hypertension.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Vasodilators
Hypertension II: Pathophysiology

